Bartlett & Co. LLC cut its holdings in shares of Agilent Technologies, Inc. (NYSE:A – Get Rating) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,359 shares of the medical research company’s stock after selling 147 shares during the period. Bartlett & Co. LLC’s holdings in Agilent Technologies were worth $354,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. boosted its position in Agilent Technologies by 1.9% in the third quarter. BlackRock Inc. now owns 32,943,190 shares of the medical research company’s stock worth $4,004,242,000 after purchasing an additional 629,153 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Agilent Technologies by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 24,955,720 shares of the medical research company’s stock valued at $3,033,368,000 after buying an additional 257,455 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Agilent Technologies by 1.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 16,652,764 shares of the medical research company’s stock valued at $1,977,848,000 after buying an additional 223,279 shares in the last quarter. State Street Corp lifted its position in shares of Agilent Technologies by 0.6% during the 3rd quarter. State Street Corp now owns 13,152,295 shares of the medical research company’s stock valued at $1,598,661,000 after buying an additional 73,495 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Agilent Technologies by 10.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,478,670 shares of the medical research company’s stock valued at $787,483,000 after buying an additional 627,517 shares in the last quarter.
Agilent Technologies Price Performance
Shares of Agilent Technologies stock opened at $133.18 on Friday. The stock has a market cap of $39.38 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.03 and a beta of 1.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.53 and a current ratio of 2.11. The stock has a 50 day moving average price of $148.54 and a 200-day moving average price of $142.83. Agilent Technologies, Inc. has a one year low of $112.52 and a one year high of $160.26.
Agilent Technologies declared that its board has initiated a share buyback plan on Monday, January 9th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to buy up to 4.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.
Agilent Technologies Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 26th. Investors of record on Tuesday, April 4th will be issued a dividend of $0.225 per share. This represents a $0.90 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date is Monday, April 3rd. Agilent Technologies’s payout ratio is currently 20.32%.
Analyst Ratings Changes
A number of research analysts have recently weighed in on A shares. KeyCorp lifted their price objective on Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a research report on Tuesday, November 22nd. Citigroup lifted their target price on Agilent Technologies from $145.00 to $150.00 and gave the company a “neutral” rating in a research note on Tuesday, November 22nd. Robert W. Baird lifted their target price on Agilent Technologies from $170.00 to $174.00 and gave the company an “outperform” rating in a research note on Wednesday, March 1st. Cowen lifted their target price on Agilent Technologies from $160.00 to $168.00 in a research note on Tuesday, November 22nd. Finally, Cowen lifted their target price on Agilent Technologies from $160.00 to $168.00 in a research note on Tuesday, November 22nd. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $163.31.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Featured Stories
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Get Rating).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
